Dick de Zeeuw
Rijksuniversiteit Groningen
H-index: 127
Europe-Netherlands
Top articles of Dick de Zeeuw
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL | Kidney International Reports | Katherine Tuttle Sibylle Hauske Shimoli V Shah Lisa Cronin Zhichao Sun | 2024/4/1 |
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled … | Diabetes, Obesity and Metabolism | Stefan R Bornstein Dick de Zeeuw Hiddo JL Heerspink Friedrich Schulze Lisa Cronin | 2024/3/18 |
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial | The Lancet | Katherine R Tuttle Sibylle J Hauske Maria Eugenia Canziani Maria Luiza Caramori David Cherney | 2024/1/27 |
Study design and baseline characteristics for aldosterone synthase inhibition in CKD | Am J Nephrol | Katherine R Tuttle Peter Rossing Sibylle J Hauske Lisa Cronin Joanna Hussain | 2023/10/30 |
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A … | Diabetes, Obesity and Metabolism | Amy Kang Brendan Smyth Brendon L Neuen Hiddo JL Heerspink Gian Luca Di Tanna | 2023/8 |
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering | BMJ Open Diabetes Research and Care | David M Charytan Kenneth W Mahaffey Meg J Jardine Christopher P Cannon Bruce Neal | 2023/6/1 |
Regional variation in hemoglobin distribution among individuals with CKD: the ISN international network of CKD cohorts | Kidney International Reports | Mark Canney Dilshani Induruwage Mila Tang Natalia Alencar de Pinho Lee Er | 2023/10/1 |
Longitudinal relationship between albuminuria in infancy and childhood | Pediatric Nephrology | Valentina Gracchi Sophie M van den Belt Eva Corpeleijn Dick de Zeeuw Hiddo JL Heerspink | 2023/8 |
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study | European heart journal | Patrick B Mark Juan J Carrero Kunihiro Matsushita Yingying Sang Shoshana H Ballew | 2023/4/1 |
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease | Cardiovascular Diabetology | J David Smeijer Donald E Kohan Peter Rossing Ricardo Correa-Rotter Adrian Liew | 2023/9/16 |
Kidney and cardiovascular effects of canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial | American Journal of Kidney Diseases | Tae Won Yi Brendan Smyth Gian Luca Di Tanna Clare Arnott Kathryn Cardoza | 2023/7/1 |
Aldosterone Synthase Inhibition with or Without Background Sodium Glucose Cotransporter 2 Inhibition in CKD: A Phase II Clinical Trial | Katherine R Tuttle Sibylle J Hauske Lisa Cronin Zhichao Sun Dick de Zeeuw | 2023 | |
The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial | Diabetes, Obesity and Metabolism | Jie Yu Arianne N Sweeting Chris Gianacas Lauren Houston Vivian Lee | 2023/12 |
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial | Diabetes, Obesity and Metabolism | David ZI Cherney Dick de Zeeuw Hiddo JL Heerspink Jose Cardona Marc Desch | 2023/8 |
Phase ii dose-selection, randomised double-blind trial of the asi, bi 690517, alone and in combination with empa in people with ckd | Nephrology Dialysis Transplantation | Katherine Tuttle Peter Rossing Lisa Cronin Sibylle Hauske Joanna Hussain | 2023/6/1 |
S-09-1: HIGH BLOOD PRESSURE AND ALBUMINURIA, BOTH THERAPEUTIC TARGETS FOR CARDIOVASCULAR DISEASE PROTECTION? | Journal of Hypertension | Dick de Zeeuw | 2023/1/1 |
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic … | Kidney International | Kam Wa Chan J David Smeijer Meir Schechter Niels Jongs Priya Vart | 2023/12/1 |
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan | Diabetes, Obesity and Metabolism | J David Smeijer Donald E Kohan Dick de Zeeuw Hiddo JL Heerspink | 2023/8 |
# 3318 phase ii dose-selection, randomised Double-blind trial of the Asi, bi 690517, alone and in combination with Empa in people with ckd | Nephrology Dialysis Transplantation | Katherine Tuttle Peter Rossing Lisa Cronin Sibylle Hauske Joanna Hussain | 2023/6 |
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP | European journal of preventive cardiology | Kunihiro Matsushita Stephen Kaptoge Steven HJ Hageman Yingying Sang Shoshana H Ballew | 2023/1/1 |
